The stock of Vigil Neuroscience Inc (NASDAQ: VIGL) has increased by 6.52 when compared to last closing price of 3.99.Despite this, the company has seen a gain of 1.43% in its stock price over the last five trading days. globenewswire.com reported 2024-07-24 that – Safety, tolerability, pharmacokinetic and pharmacodynamic profile of VG-3927 supports continued development as potential once-daily oral therapy for Alzheimer’s disease (AD) –
Is It Worth Investing in Vigil Neuroscience Inc (NASDAQ: VIGL) Right Now?
The 36-month beta value for VIGL is at 2.01. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VIGL is 15.54M, and currently, shorts hold a 13.82% of that float. The average trading volume for VIGL on July 25, 2024 was 546.06K shares.
VIGL’s Market Performance
VIGL’s stock has seen a 1.43% increase for the week, with a 9.54% rise in the past month and a 60.38% gain in the past quarter. The volatility ratio for the week is 8.99%, and the volatility levels for the past 30 days are at 9.63% for Vigil Neuroscience Inc The simple moving average for the past 20 days is 4.65% for VIGL’s stock, with a 9.08% simple moving average for the past 200 days.
Analysts’ Opinion of VIGL
Many brokerage firms have already submitted their reports for VIGL stocks, with Morgan Stanley repeating the rating for VIGL by listing it as a “Underweight.” The predicted price for VIGL in the upcoming period, according to Morgan Stanley is $4 based on the research report published on December 19, 2023 of the previous year 2023.
JMP Securities, on the other hand, stated in their research note that they expect to see VIGL reach a price target of $23. The rating they have provided for VIGL stocks is “Mkt Outperform” according to the report published on October 18th, 2023.
Mizuho gave a rating of “Buy” to VIGL, setting the target price at $15 in the report published on March 31st of the previous year.
VIGL Trading at 10.16% from the 50-Day Moving Average
After a stumble in the market that brought VIGL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.00% of loss for the given period.
Volatility was left at 9.63%, however, over the last 30 days, the volatility rate increased by 8.99%, as shares surge +14.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +33.65% upper at present.
During the last 5 trading sessions, VIGL rose by +1.43%, which changed the moving average for the period of 200-days by -22.73% in comparison to the 20-day moving average, which settled at $4.09. In addition, Vigil Neuroscience Inc saw 25.74% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VIGL starting from Magovcevic-Liebisch Ivana, who purchase 4,000 shares at the price of $3.75 back on Nov 20 ’23. After this action, Magovcevic-Liebisch Ivana now owns 207,687 shares of Vigil Neuroscience Inc, valued at $15,000 using the latest closing price.
Stock Fundamentals for VIGL
Current profitability levels for the company are sitting at:
- -46.28 for the present operating margin
- 0.58 for the gross margin
The net margin for Vigil Neuroscience Inc stands at -42.8. The total capital return value is set at -0.77. Equity return is now at value -60.18, with -52.16 for asset returns.
Based on Vigil Neuroscience Inc (VIGL), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -5.14. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -85.65.
Currently, EBITDA for the company is -88.47 million with net debt to EBITDA at 0.43. When we switch over and look at the enterprise to sales, we see a ratio of 62.88. The receivables turnover for the company is 1.29for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.38.
Conclusion
In conclusion, Vigil Neuroscience Inc (VIGL) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
